<DOC>
	<DOCNO>NCT00425386</DOCNO>
	<brief_summary>RATIONALE : Sunitinib erlotinib may stop growth tumor cell block enzyme need cell growth block blood flow tumor . Giving sunitinib together erlotinib may kill tumor cell . PURPOSE : This phase II trial study best dose erlotinib give together sunitinib see well work treat patient unresectable metastatic kidney cancer .</brief_summary>
	<brief_title>Sunitinib Erlotinib Treating Patients With Unresectable Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose erlotinib hydrochloride administer sunitinib malate patient unresectable metastatic renal cell carcinoma . - Determine 8-month progression-free survival patient treat regimen . Secondary - Determine safety sunitinib malate erlotinib hydrochloride patient . - Determine duration response patient . - Determine proportion patient whose best overall response complete response , partial response , stable disease , progressive disease . - Determine overall survival patient treat regimen . - Determine maximum percent reduction tumor measurement patient treat regimen . - Collect blood tissue patient future correlative study . OUTLINE : This open-label , multicenter , dose-escalation study erlotinib hydrochloride . Patients receive oral sunitinib malate daily day 1-28 oral erlotinib hydrochloride daily day 1-42 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose 33 % patient experience dose-limiting toxicity . Once MTD determine , patient treat erlotinib hydrochloride MTD sunitinib malate . Patients undergo blood tumor specimen collection periodically study future correlative study . PROJECTED ACCRUAL : A total 49 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma component clear cell papillary carcinoma Unresectable metastatic disease ( radiologically clinically confirm ) Measurable disease ( ≥ 1 site ) No know brain metastasis adequately treat radiotherapy and/or surgery PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ No grade 3 hemorrhage within past 4 week Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2.5 time ULN ( &lt; 5 time ULN due underlie disease ) No chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) Creatinine ≤ 1.5 time ULN None follow cardiovascular condition within past 12 month : Myocardial infarction Severe/unstable angina Coronary/peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism Ongoing cardiac dysrhythmia ≥ grade 2 Atrial fibrillation grade Prolongation correct QT ( QTc ) interval &gt; 450 msec male &gt; 470 msec female Left Ventricular Ejection Fraction ( LVEF ) normal Multigated Acquisition ( MUGA ) echocardiogram No hypertension uncontrolled medical therapy No active malignancy within past 5 year except basal cell skin cancer cervical carcinoma situ No uncontrolled adrenal insufficiency No uncontrolled hypothyroidism Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) No impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug No severe acute chronic medical psychiatric condition laboratory abnormality would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior major surgery More 4 week since prior cytotoxic chemotherapy ( 6 week nitrosoureas mitomycin C ) More 4 week since prior radiotherapy No prior radiotherapy &gt; 25 % bone marrow More 28 day since prior investigational agent No prior sunitinib malate No prior antiepidermal growth factor receptor therapy ( e.g. , erlotinib hydrochloride , panitumumab , cetuximab , gefitinib ) No concurrent therapeutic warfarin Lowdose oral warfarin ≤ 2 mg daily deep vein thrombosis prophylaxis allow maximum tolerated dose erlotinib hydrochloride determine No concurrent Hypericum perforatum ( St. John 's wort ) No concurrent chemotherapy biologic therapy No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>